Methods for making cytokine compositions from tissues using non-centrifugal methods
View Patent ↗Non-centrifugal methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The solution rich in IL-1ra can also include at least one of sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1 RII.
1. A method for generating a solution rich in interleukin-1 receptor antagonist (IL-1ra) comprising:
obtaining a liquid volume comprising white blood cells by separating white blood cells from a tissue comprising any one of: (a) whole blood, bone marrow aspirate, adipose tissue; (b) a fraction thereof; or (c) a mixture of any of the foregoing, using dielectrophoretic field-flow-fractionation (DEP-FFF), wherein separating the white blood cells concentrates the white blood cells to at least about 15,000/μl; and
contacting the liquid volume comprising white blood cells with a solid extraction material to obtain a solution rich in IL-1ra.
2. The method according to claim 1 , wherein the solution rich in IL-1ra further comprises one or more proteins selected from the group consisting of epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet-derived growth factor BB (PDGF-BB), and soluble interleukin one receptor II (sIL-1RII).
3. The method according to claim 1 , wherein the solution rich in IL-1ra comprises:
(i) interleukin-1 receptor antagonist (IL-1ra) at a concentration of at least about 10,000 pg/ml;
(ii) soluble Tumor Necrosis Factor Receptor 1 (sTNF-R1) at a concentration of at least about 1,200 pg/ml; and
(iii) EGF, HGF, PDGF-BB, or soluble interleukin one receptor II (sIL-1RII) at a concentration of at least about 2,000 pg/ml.
4. The method according to claim 1 , wherein the solid extraction material comprises any one of corundum, quartz, titanium, dextran, agarose, polyacrylamide, polystyrene, polyethylene, polyvinyl chloride, polypropylene, or a combination of any of the foregoing.
5. The method according to claim 4 , wherein the solid extraction material comprises polyacrylamide.
6. The method according to claim 1 , wherein the solid extraction material comprises a form selected from the group consisting of a bead, fiber, powder, porous material, and combinations thereof.
7. The method according to claim 1 , wherein the surface of the solid extraction material is etched to increase its surface area.
8. The method according to claim 1 , wherein the contacting is for a period of time from about 30 seconds to about 2 hours.
9. The method according to claim 1 , wherein the contacting comprises subjecting the liquid to an electromagnetic field.
10. The method according to claim 9 , wherein the electromagnetic field comprises a pulsed electromagnetic field or a capacitively coupled electromagnetic field.
11. A method of preparing an enriched biological solution, comprising:
(a) separating white blood cells from a tissue selected from whole blood, bone marrow aspirate, adipose tissue, a fraction thereof, or a mixture thereof to produce a volume of concentrated white blood cells, including subjecting the tissue to di electrophoretic field-flow-fractionation (DEP-FFF), wherein the separating separates at least about one-half of red blood cells in the tissue from the volume of white blood cells;
(b) mixing the volume of white blood cells with a liquid medium to form a cytokine cell suspension, wherein the cytokine cell suspension comprises white blood cells, and at least one of platelets, adipose stromal cells, and mesenchymal stromal cells;
(c) contacting the cytokine cell suspension with polyacrylamide beads for a period of time between about 30 seconds and about 72 hours; and
(d) separating liquid from the polyacrylamide beads to obtain a solution rich in IL-1ra and rich in at least one of epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet-derived growth factor-BB (PDGF-BB), and soluble interleukin-1 receptor II (sIL-1RII).
12. The method according to claim 11 , wherein the tissue is autologous with the subject.
13. The method according to claim 11 , wherein the solution rich in IL-1ra has an IL-1ra concentration of at least about 10,000 pg/ml.
14. The method according to claim 11 , wherein the solution rich in IL-1ra further comprises at least one protein selected from soluble tumor necrosis factor receptor II (sTNF-RII), insulin-like growth factor-I (IGF-I), platelet-derived growth factor-AB (PDGF-AB), vascular endothelial growth factor (VEGF), and transforming growth factor-β1 (TGF-β1), wherein the concentration of the selected protein in the solution is greater than the concentration of the selected protein in normal blood.
15. The method according to claim 11 , wherein separating comprises:
(a) diluting the tissue comprising white blood cells in a sucrose buffer to form a biological sample;
(b) loading the biological sample into a chamber comprising a top plate and a bottom plate, wherein the top plate and bottom plate are coupled to microelectrodes;
(c) applying a dielectrophoretic (DEP) field to the biological sample, wherein white blood cells are suspended in the biological sample; and
(d) isolating a volume of white blood cells by flowing a carrier fluid through the chamber.
16. The method according to claim 15 , wherein the DEP field comprises a frequency of about 10 kHz.
17. The method according to claim 11 , wherein the white blood cells are concentrated to at least about 15,000/μl.
18. The method according to claim 11 , further comprising:
(e) administering the solution rich in IL-1ra to a mammalian subject.
19. A method for generating a biological solution enriched in anti-inflammatory cytokines and growth factors, the method comprising:
subjecting a tissue comprising any one of: (a) whole blood, bone marrow aspirate, adipose tissue; (b) a fraction thereof; or (c) a combination of any of the foregoing, to dielectrophoretic field-flow-fractionation to separate white blood cells from the tissue to produce a volume of white blood cells at a concentration of at least about 15,000/μl, wherein the volume of white blood cells includes about one-half or less of red blood cells from the tissue; and
contacting the volume of white blood cells with a solid extraction material to obtain the biological solution enriched in at least one protein selected from interleukin-1 receptor II, platelet-derived growth factor BB, epidermal growth factor, and hepatocyte growth factor.
20. The method of claim 19 , wherein the at least protein is at a concentration of at least 2,000 pg/ml.
21. The method of claim 19 , wherein the at least one protein is present in a concentration greater than the concentration of the at least one protein in normal blood.
22. The method of claim 19 , wherein the at least one protein is a growth factor at a concentration of at least about 1,500 pg/ml.
23. The method of claim 19 , wherein the solution further comprises at least one supplemental protein selected from soluble tumor necrosis factor receptor II (sTNF-RII), insulin-like growth factor-I (IGF-I), platelet-derived growth factor-AB (PDGF-AB), vascular endothelial growth factor (VEGF), and transforming growth factor-β1 (TGF-β1), wherein the concentration of the selected supplemental protein in the solution is greater than the concentration of the selected supplemental protein in normal blood.
24. The method of claim 19 , wherein the contacting comprises subjecting the white blood cells to an electromagnetic field.
25. The method of claim 19 , wherein the contacting is for a period of less than 30 minutes.
26. The method according to claim 19 , wherein the solid extraction material comprises any one of corundum, quartz, titanium, dextran, agarose, polyacrylamide, polystyrene, polyethylene, polyvinyl chloride, polypropylene, or a combination of any of the foregoing.